China ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis

China Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Executive Analysis

The China Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $2.37 Bn in 2022 and is projected to reach $4.73 Bn in 2030, exhibiting a CAGR of 9% during the forecast period. According to the South China Morning Post's most recent healthcare report, China's combined pharmaceutical and biopharma R&D expenditure will increase at a compound annual rate of 23% until 2023, reaching $49 Bn. By then, 23% of the global total for drug finding and testing will be spent on pharmaceutical and biopharma R&D in China. Before 2030, the SCMP research found that China could be on par with America and Europe in terms of its ability to produce best-in-class medications. $10 Bn of all exports in Q1 were made up of medical supplies from China, which also produces 40% of the Application programming interface (API) used globally. China is the second-largest market in the globe for healthcare with a spending of $3.5 Tn.

One of the most prevalent juvenile psychiatric conditions is Attention Deficit Hyperactivity Disorder (ADHD), which manifests as impulsivity, hyperactivity, and inattention. As a significant public health issue, ADHD has been linked to a broad range of negative health outcomes for those who are affected. The world's largest population of children and teenagers is found in China and 5.7% of Chinese children and teenagers have ADHD. Chinese children may experience chronic stress as a result of their country's highly competitive educational system and mounting scholastic pressures, making them more vulnerable to mental health issues like ADHD. According to government figures, over 90% of childhood, ADHD cases in China still go undiagnosed. Only one-third of children who are diagnosed even go on to receive medication or behavioral treatment.

In China, drug therapy can be considered after thoroughly discussing the benefits and drawbacks of drug use with parents. For patients who are of school-age, drug therapy, behavioral therapy, or a combination of both is favored. Medication is still favored for patients whose bodily functions are affected after adulthood (age 18). Cognitive behavioral therapy, however, may be an option if a patient refuses medication, the medication is ineffective, or the medication has unacceptably high side effects.

In China, Traditional Chinese treatment (TCM) is a widely accepted and accepted complement to Western treatment. The Liver and Kidneys are the primary organs where Liver-Kidney Yin imbalance manifests itself in ADHD, according to TCM. It's conceivable that ADHD has a genetic component because, according to TCM, your constitution is built on the kidney. Typically, a child's Yin is inadequate; without enough Yin, there is not enough Yang to maintain equilibrium. Consequently, there is a higher chance of having a Liver-Kidney Yin deficit. TCM therapy for ADHD typically uses Chinese herbs, medications, and/or acupuncture to balance the Yin and Yang of the five Organs. Typically, the healing process is prolonged and complicated.

Market Dynamics

Market Growth Drivers

Since there are many young people in China, there is a sizable prospective market for the treatment of ADHD. Patients and their families are seeking therapy for the condition as they become more aware of it, which is helping the China ADHD therapeutics market to expand. The Chinese government is offering more assistance and resources for the identification and therapy of ADHD, which is assisting in the market's expansion. The availability of advanced therapies, such as non-stimulant medications and behavioral therapies, is encouraging the development of the ADHD market in China.

Market Restraints

In China, there is a stigma associated with mental health conditions, including ADHD, and misunderstandings of the disease may result in neglectful treatment. A further issue is a general opposition to giving children medicines in China. The traditional Chinese view that all drugs are somewhat harmful to the body is one that many families cling to as major restraint to the growth of China's ADHD therapeutics market.

Competitive Landscape

Key Players

• Jiangsu Hengrui Medicine (CHN)
• BeiGene (CHN)
• Chongqing Zhifei Biological Products (CHN)
• Shanghai Fosun Pharmaceutical (CHN)
• Huadong Medicine (CHN)
• Adlon Therapeutics
• Amnel Pharmaceuticals
• Aytu Biopharma
• American Brivision
• Cingulate
• Eli Lilly
• GSK

Healthcare Policies and Regulatory Landscape

The National Medical Products Administration (NMPA), formerly the China Food and Drug Administration (CFDA), which answers to the State Administration of Market Regulation (SAMR), is responsible for regulating drugs and medical products. The NMPA is in charge of carrying out drug registration and approvals, giving advice to provincial authorities, and collaborating with provincial investigators to assign clinical trial facility inspections and foreign inspections. The classification of the drug product in accordance with NMPA regulations determines the licensing process for pharmaceuticals in China. In China, the classification determines the regulatory clearance procedure. To complete the registration procedure with the National Medical Products Administration, a foreign manufacturer or applicant must have a legally designated local agent in China who is in charge of pharmaceutical regulatory matters. The NMPA must receive the applicant's Marketing Authorization Holding (MAH) registration. According to NMPA regulations, the MAH must submit an application for the renewal certificate six months before the Drug Approval License's five-year validity term is through.